Targeted Therapies in Oncology
November 2012
Volume: 1
Issue: 4
September 2012
Volume: 1
Issue: 3
June 2012
Volume: 1
Issue: 2
March 2012
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5